Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2024.11.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing institutional responsibility in scientific misconduct: A case study of enoximone research by Joachim Boldt.
Clin Trials
December 2024
Institute of General Practice and Public Health, Claudiana-College of Health Professions, Bolzano, Italy.
Background: Enoximone, a phosphodiesterase III inhibitor, was approved in Germany in 1989 and initially proposed for heart failure and perioperative cardiac conditions. The research of Joachim Boldt and his supervisor Gunter Hempelmann came under scrutiny after investigations revealed systematic scientific misconduct leading to numerous retractions. Therefore, early enoximone studies by Boldt and Hempelmann from 1988 to 1991 were reviewed.
View Article and Find Full Text PDFFurther Retractions of Dr. Joachim Boldt in the Journal of Cardiothoracic and Vascular Anesthesia.
J Cardiothorac Vasc Anesth
November 2024
Department of Anesthesiology, University of California, San Diego, CA.
Further Retractions of Articles by Joachim Boldt.
Crit Care Med
June 2022
Department of Public Health, Medical Decision Making and HTA, University of Health Sciences, Medical Informatics and Technology, Hall in Tyrol, Austria.
Axonal degeneration (AxD) is a pathological hallmark of many neurodegenerative diseases. Deciphering the morphological patterns of AxD will help to understand the underlying mechanisms and develop effective therapies. Here, we evaluated the progression of AxD in cortical neurons using a novel microfluidic device together with a deep learning tool that we developed for the enhanced-throughput analysis of AxD on microscopic images.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!